We narrowed to 1,062 results for: REP

#202199-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (#202199). In addition to the viral particles, you will also receive purified pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized opsin PdCO. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#202199-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE (#202199). In addition to the viral particles, you will also receive purified pAAV_hSyn-SIO-stChrimsonR-EGFP-P2A-PdCO-miniWPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of bicistronically soma-targeted ChrimsonR in frame with EGFP and the optimized opsin PdCO. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#135635-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#105322-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE (#105322). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

June 13, 2019

Academic Institutions and Nonprofits only

#104493-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-FLEX-jGCaMP7b-WPRE (#104493). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7b-WPRE plasmid DNA. Synapsin-driven, Cre-dependent jGCaMP7b expression. jGCaMP7b expression exhibits the brightest resting fluorescence and can be used for imaging of small neuronal processes (dendrites and axons). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Nov. 14, 2019

Academic Institutions and Nonprofits only

#172908-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-Ace2N-4AA-mNeon-ST A122D WPRE (#172908). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-Ace2N-4AA-mNeon-ST A122D WPRE plasmid DNA. Syn-driven, Cre-dependent Ace2N-4AA-mNeon-ST A122D expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Abdelfattah et al Neuron. 2023 Mar 28:S0896-6273(23)00205-

Feb. 14, 2022

Academic Institutions and Nonprofits only

#105321-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

July 12, 2019

Academic Institutions and Nonprofits only

#135633-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-C1V1-eYFP (#135633). In addition to the viral particles, you will also receive purified pAAV-S5E2-C1V1-eYFP plasmid DNA. Expression of red-shifted opsin C1V1 fused to EYFP under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213943-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only